NYSE American · AZTRHealthcarePharmaceuticals

Azitra financials

$0.1306−22.95%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
Revenue$0.00$7.5K$686.0K
Gross profit$0.00$7.5K$686.0K
Gross margin—100.0%100.0%
Operating income-$11.0M-$11.0M-$7.5M
Net income-$11.0M-$9.0M-$12.6M
Net margin—−119566.6%−1842.4%
Diluted EPS$-2.25$-15.70$-366.17
EBITDA-$10.8M-$10.9M-$7.0M
Operating cash flow-$11.2M-$10.2M-$7.4M
Free cash flow-$11.2M-$10.2M-$7.4M
Diluted shares4.9M0.6M0.0M

Balance sheet

Period endDec 31Dec 31Dec 31
Cash & equivalents$2.1M$4.6M$1.8M
Short-term investments$0.00$0.00$0.00
Total debt$209.1K$26.2K$40.8K
Total assets$5.0M$7.4M$5.1M
Total liabilities$1.2M$1.7M$2.2M
Shareholders' equity$3.8M$5.7M$2.9M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology